PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩7 per share · Prices as of the 2026-10-02 close
Bolak swung from an operating loss in 2024 back to profit in 2025 and has sustained earnings through the first half of 2026, though revenue has stayed range-bound near KRW 50 billion for several years.
2025 revenue reached KRW 50.1 billion with operating profit of KRW 2.23 billion, reversing the prior year's operating loss of KRW 1.79 billion
Combined net profit of KRW 1.47 billion in Q1-Q2 2026 shows continued earnings, though operating profit had sharply dropped to KRW 50 million in Q4 2025
Core products include pineapple essence, sodium saccharin, and CMC calcium among food additives and pharmaceutical raw materials
Debt-to-equity ratio stood at 21.6% in 2025, indicating a relatively stable financial structure
Operations are concentrated at a single domestic production site, with revenue concentrated in a small number of product lines
Bolak was established in 1959 as Korea Agricultural Industry Co. and later renamed Bolak, operating as a specialized manufacturer of food additives and pharmaceutical raw materials.
Its product lineup spans food flavors such as pineapple essence, sweeteners like sodium saccharin, Bolak CMC calcium (carboxymethylcellulose calcium), gum base, herbal medicine materials, functional food ingredients, and new natural cosmetics raw materials.
According to an industry trade publication, revenue was once composed of pineapple essence at 55.9%, Bolak CMC calcium at 24.5%, and sodium saccharin at 16.9%, while more recent data points to a mix of roughly 47% for the pineapple essence line, about 29% for sodium saccharin, and around 21% for CMC calcium.
Its main customers are domestic food, confectionery, and beverage manufacturers that source flavor and additive raw materials from the company. Bolak holds certification under Korea's Good Manufacturing Practice standard for raw pharmaceutical materials (BGMP) as well as ISO 9001 quality certification.
Production is concentrated at a single domestic plant in Hwaseong, Gyeonggi Province, with both domestic and export revenue attributed to this one site, as the company operates no overseas manufacturing base.
Because relatively few specialized producers exist in the flavor and food-additive segment, new product development capability responsive to shifting consumer preferences is cited as a key competitive factor.
The company states it continues research and development aimed at food flavors, functional materials, and natural cosmetics ingredients in line with market trends.
| Quarter | Revenue | Operating profit | Op. margin |
|---|---|---|---|
| 2025Q2 | ₩13.7B | ₩900M | 6.5% |
| 2025Q3 | ₩11.9B | ₩1B | 8.2% |
| 2025Q4 | ₩11.4B | ₩50,000,168 | 0.4% |
| 2026Q1 | ₩11.2B | ₩600M | 5.0% |
| 2026Q2 | ₩12.5B | ₩700M | 5.5% |
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2022 | ₩48.4B | ₩3.3B | ₩3.1B | 6.8% | 6.3% | 25.9% |
| 2023 | ₩46.8B | ₩500M | ₩900M | 1.1% | 1.8% | 18.8% |
| 2024 | ₩47.6B | -₩1.8B | -₩1.5B | −3.8% | −3.2% | 27.1% |
| 2025 | ₩50.1B | ₩2.2B | ₩2.3B | 4.4% | 4.8% | 21.6% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-08-23
Bolak's annual revenue moved gradually from KRW 48.4 billion in 2022 to KRW 46.8 billion in 2023, KRW 47.6 billion in 2024, and KRW 50.1 billion in 2025.
Operating profit, however, fell sharply from KRW 3.28 billion (6.8% operating margin) in 2022 to KRW 0.51 billion (1.1%) in 2023, then turned negative at KRW -1.79 billion (-3.8%) in 2024.
In 2025, alongside revenue growth, operating profit returned to positive territory at KRW 2.23 billion (4.4% margin), and net profit attributable to owners improved from KRW -1.51 billion in 2024 to KRW 2.34 billion in 2025.
On a quarterly basis, the company posted revenue of KRW 13.7 billion and operating profit of KRW 0.89 billion in Q2 2025, followed by KRW 11.9 billion in revenue and KRW 0.98 billion in operating profit in Q3 2025, sustaining solid momentum through the third quarter.
Q4 2025, however, saw revenue fall to KRW 11.4 billion while operating profit collapsed to just KRW 50 million, suggesting seasonal or one-off cost factors may have been at play.
In 2026, the company recorded revenue of KRW 11.2 billion and operating profit of KRW 0.56 billion in Q1, followed by revenue of KRW 12.5 billion and operating profit of KRW 0.68 billion in Q2, indicating a renewed improvement in profitability.
On the bottom line, net profit attributable to owners in Q2 2026 reached KRW 0.93 billion, exceeding operating profit of KRW 0.68 billion, implying a contribution from non-operating items.
Operating cash flow expanded sharply from KRW 0.9 billion in 2024 to KRW 7.17 billion in 2025, indicating that the earnings recovery also translated into stronger cash generation.
Still, across the four years from 2022 to 2025, operating margins swung between 6.8%, 1.1%, -3.8%, and 4.4%, underscoring a fairly high degree of profitability volatility.
The food-additive and flavor industry in which Bolak operates is closely tied to downstream demand from the food, confectionery, and beverage sectors. The global spices and seasonings market is projected to grow moderately, from roughly USD 21.14 billion in 2025 to USD 21.98 billion in 2026.
The sodium saccharin market, one of the company's core products, is also projected to expand from USD 423.99 million in 2024 to USD 670.83 million by 2033 at a 5.23% CAGR, with research emerging on new pharmaceutical and biomedical applications such as antibiotic-resistance suppression alongside traditional sweetener demand.
In processed food segments such as flavored candy, health-oriented consumption trends and demand for sugar-free and functional products are cited as growth drivers.
Domestically, the relatively small number of specialized flavor and additive producers creates some entry barriers, while the sensitivity of these products to consumer preference makes new product development capability and quality control key competitive factors.
Although Bolak maintains a quality management system including BGMP certification, its single domestic production site leaves it in a comparatively limited position versus larger, more diversified chemical and food-material producers in terms of scale economies and geographic diversification.
Bolak states it continues research and development responsive to trend shifts in food flavors, gum base, herbal medicine materials, functional food ingredients, and new natural cosmetics raw materials.
No specific public guidance on revenue or profit targets, nor any newly confirmed capacity expansion or order-backlog plans, have been identified, suggesting that future performance will likely hinge largely on demand for its existing core products (pineapple essence, sodium saccharin, CMC calcium) and cost management.
The return to profit in 2025 and the sustained earnings through the first half of 2026 appear to reflect a combination of revenue recovery and cost-of-goods management, and whether this trend continues through the second half remains a point to watch.
However, given the history of a sharp margin deterioration in a single quarter such as Q4 2025, seasonal factors or volatility in specific costs (raw material purchases, inventory valuation, etc.) can have a meaningful impact on results.
The company's BGMP-certified raw pharmaceutical ingredient production capability can be viewed as a factor that keeps open the possibility of business expansion beyond food additives into pharmaceutical raw materials.
Given the business's exposure to imported raw materials, foreign exchange rates and international raw material price trends remain variables that warrant ongoing observation on the cost side.
Bolak turned from a net loss in 2024 to net profit in 2025 and has sustained that earnings trend through the first half of 2026, confirming an improving direction in its profit-and-loss recovery.
That said, given the substantial swings in operating margin over the past four years, relying on a single point-in-time profitability metric to assess valuation carries limits, and this volatility should be weighed accordingly.
The shares tend to trade in a range showing a modest premium to net asset value, which could partly reflect market expectations about the durability of the earnings recovery.
On the dividend side, the company has a history of paying annual cash dividends, though the dividend yield itself tends to run below the sector average.
Ultimately, valuation for this name is likely to hinge heavily on the stability of future quarterly earnings—specifically, whether a margin collapse similar to that seen in Q4 2025 recurs.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-08-23
After posting an operating loss of KRW 1.79 billion in 2024, Bolak returned to profit with operating income of KRW 2.23 billion in 2025. Earnings momentum has continued into 2026, with operating profit of KRW 0.56 billion in Q1 and KRW 0.68 billion in Q2. Revenue also grew gradually from KRW 46.8 billion in 2023 to KRW 50.1 billion in 2025.
Because relatively few domestic manufacturers specialize in flavors and food additives, a certain degree of entry barrier exists in the market.
Bolak holds BGMP certification as a high-quality raw pharmaceutical material producer along with ISO 9001 and other quality certifications, which can support long-term customer relationships.
The debt-to-equity ratio remained low at 21.6% in 2025, and operating cash flow expanded sharply from KRW 0.9 billion in 2024 to KRW 7.17 billion in 2025. Low leverage combined with recovering cash generation supports financial flexibility going forward.
Annual revenue ranged only between KRW 46.8 billion and KRW 50.1 billion from 2022 through 2025, without showing a clear growth trajectory. With no clearly identified new growth driver, the revenue structure remains heavily dependent on existing core products.
Quarterly earnings swings have been substantial, with operating profit dropping sharply from KRW 0.98 billion in Q3 2025 to just KRW 50 million in Q4 2025. If specific costs or seasonal factors recur, this could reduce the reliability of full-year forecasts.
While Bolak has a history of paying annual cash dividends, the dividend yield tends to run below the sector average. No clear signal of expanded shareholder returns has been identified so far.
Given the business's partial reliance on imported flavor and chemical raw materials, rising international commodity prices or currency fluctuations can directly affect cost of goods sold. The sharp margin contraction in Q4 2025 may not be unrelated to such cost factors.
Safety standards and labeling regulations for artificial sweeteners including sodium saccharin and other food additives continue to evolve across jurisdictions. Tightening food safety regulations domestically or abroad could affect sales or cost structures for related products.
Revenue is concentrated in a small number of products such as pineapple essence, sodium saccharin, and CMC calcium, and production is limited to a single domestic site. A slowdown in demand for a specific product or an issue at the production facility could have a relatively large impact on results.
Check the Q3 2026 earnings disclosure to see whether the profit recovery continues and whether a margin collapse similar to Q4 2025 recurs.
Monitor imported raw material prices and foreign exchange trends to see whether cost pressures resurface or seasonal margin weakness reappears.
The finalization of FY2026 financial statements and the dividend resolution will confirm the full-year results and whether the shareholder return policy continues.
Track domestic and international regulatory developments on food additive and artificial sweetener safety standards to gauge whether regulatory risk materializes.
Bolak has manufactured food additives and pharmaceutical raw materials since its founding in 1959, with revenue concentrated in a handful of core products such as pineapple essence, sodium saccharin, and CMC calcium.
After posting an operating loss in 2024, the company returned to profit in 2025 and has sustained earnings through the first half of 2026, confirming an improving trend, though operating margins swung dramatically from 6.8% to -3.8% over four years, underscoring considerable profitability volatility.
The sharp drop in operating profit to KRW 50 million in Q4 2025 in particular highlights how seasonal or one-off cost factors can affect results.
The balance sheet remains relatively stable, supported by a low debt ratio and improved cash generation, and the existence of entry barriers in the flavor and additive market is a favorable factor.
On the other hand, revenue growth has stagnated for several years and dividend appeal lags the sector average, making the persistence of the earnings recovery and the moderation of quarterly volatility the key items to monitor going forward. This report contains no buy or sell recommendation and is provided for informational purposes only.
Report written 2026-09-05 · Data as of 2026-09-04
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.